Description
The effectiveness of biomarkers has made them essential to medicine, with successful products on the market and many products in development. This Kalorama Information report focuses on both the clinical biomarkers and research biomarkers in medicine.
Biomarkers are physiologic, genetic or biochemical parameters that provide insight into understanding disease processes and ways that medicines can work to counteract the disease. With them, diseases are detected earlier, more effective treatments can be delivered, drug reactions reduced. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body’s tissues, and can suggest a cardiovascular event when levels are high. Other markers can identify the seriousness of tumors or signal immune system problems.
These biomarkers are valuable in assessing risk, detecting current disorders or diseases, treatment assessments, drug matching, etc. In research, biomarkers are useful for drug development and determining new markers for drug targeting.
The report will provide a market analysis for five broad areas of medical biomarkers:
-
- The Market for Cancer Biomarkers (by Type of Cancer)
-
- The Market for Cardiovascular and Blood Biomarkers
-
- The Market for Endocrine and Immune Biomarkers
-
- The Market for Infectious Disease Biomarkers (by Disease)
- The Market for Neurological Disease Biomarkers
For each area, additional market detail is provided:
-
- Regional Breakout (US, EMEA, Other)
Market analysis in this report considers both the epidemiological considerations and the size patient groups, available biomarkers in each segment, and estimated percentage of biomarker use in patient treatment.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers’ level. The base year for data was 2013. Historical data was provided for the years 2008 through 2012, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2008-2013 and 2013-2018 periods for each segment covered.
Basic competitor summaries are included in each segment. The forecasted market analysis for 2014-2018 was largely based on demographic trends, new developments, biomarker development, company performance trends, merger and acquisitions, and global expansion.
Company profiles in this report include:
-
- Genoptix Medical Laboratory
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Overview
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION TO THE MEDICAL BIOMARKERS INDUSTRY
Overview
Types of Biomarkers
History and Definition of Biomarkers in Medicine
Personalized Medicine
Potential Benefits
Privacy and Public Perception
Biomarkers as Risk Assessment Tool
Biomarkers as Diagnostic Tool
Biomarkers as Screening Tool
Biomarkers as Treatment Selection Tool
Biomarkers as Therapy Monitoring Tool
Technologies
DNA Biomarkers
DNA Tumor Biomarkers
General Biomarkers
Protein Biomarkers
RNA Biomarkers
CHAPTER THREE: INDUSTRY TRENDS
The Health Industry
Population Demographics
Life Expectancy
Chronic Disease Impact
Disease and An Aging Population
Healthcare Reform in the United States
Antimicrobial Drug Resistance
BRIC Involvement
Regulatory Structure
Molecular Test Reimbursement
CHAPTER FOUR: BIOMARKERS IN CANCER
Overview
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Cellular Oncogenes
Tumor Suppressor Genes
History of Cancer
Cancer Types
Biomarker Examples
New Developments
Total Market Size and Forecast
Cancer Biomarker Market by Geographical Region
Competitor Summary
CHAPTER FIVE: BIOMARKERS IN CARDIOVASCULAR DISEASE AND BLOOD DISORDERS
Overview
The Cardiovascular System
Heart
Circulatory System
Cardiac Cycle
Coronary Circulation
Cardiac Myocytes
Molecular Contraction
Cardiovascular And Blood Diseases
Ischemic Heart Disease
Etiology
Pathophysiology
Atherosclerosis
Angina Pectoris
Acute Ischemia and Myocardial Infarction Chronic
Chronic Ischemic Cardiomyopathy
Sudden Cardiac Death
Valvular and Endocardial Diseases
Mitral Valve Disorders
Aortic Valve Disorders
Rheumatic Heart Disease
Endocarditis
Pericardial Diseases
Pericardial Effusion
Pericarditis
Myocardial Diseases
Myocarditis
Cardiomyopathy
Congenital Heart Diseases
Atrial Septal Defect
Ventral Septal Defect
Pulmonary Stenosis
Aortic Stenosis
Coarctation of the Aorta
Patent Ductus Arteriosus
Truncus Arteriosus
Transposition of the Great Arteries
Tricuspid Atresia
Congestive Heart Failure
Etiology
Cardiac Dysrhythmias
Hypertension
Risk Factors
Effects of High Blood Pressure
Blood Disorders
Hyperlipidemia
Biomarker Availability
New Developments
Total Market Size and Forecast
Cardiovascular Disease and Blood Disorder Biomarker Market by Geographical Region
Competitor Summary
CHAPTER SIX: BIOMARKERS IN ENDOCRINE AND IMMUNE DISORDERS
Overview
The Endocrine System
Hormone Function
Hormone Synthesis
Immune System
Autoimmunity
Genetic Factors
Environmental Factors
Inflammatory Disorders
Disease Overview
Classification of Endocrine Disorders
Growth Hormone Disorders
Etiology of Growth Hormone
Antidiuretic Hormone Disorders
Etiology
Thyroid Hormone Disorders
Hypothyroidism
Hyperthyroidism
Adrenocortical Hormone Disorders
Diabetes Mellitus
Type 1 Diabetes
Type 2 Diabetes
Biomarker Availability
New Developments
Total Market Size and Forecast
Endocrine and Immune Disorder Biomarker Market by Geographical Region
Competitor Summary
CHAPTER SEVEN: BIOMARKERS IN INFECTIOUS DISEASE
Overview
Infection
Infectious Diseases
HIV Disease
Hepatitis C
Human Papillomavirus (HPV)
Sepsis
Biomarker Availability
New Developments
Total Market Size and Forecast
Infectious Disease Biomarker Market by Geographical Region
Competitor Summary
CHAPTER EIGHT: BIOMARKERS IN NERVOUS SYSTEM DISORDERS 167
Overview
The Nervous System
Central Nervous System
The Brain
Nervous System Disorders
Alzheimer’s Disease
Multiple Sclerosis
Parkinson’s Disease
Stroke
Biomarker Examples
New Developments
Total Market Size and Forecast
Nervous System Disorder Biomarker Market by Geographical Region
Competitor Summary
CHAPTER NINE: MARKET SUMMARY
Market Considerations
Market Overview
Medical Biomarkers Market by Application
Medical Biomarkers Market by Geographical Region
CHAPTER TEN: COMPANY PROFILES
Introduction
20/20 GeneSystems, Inc.
Company Overview
Abbott Laboratories
Company Overview
Affymetrix
Company Overview
Agendia, Inc. USA
Company Overview
Alere, Inc
Company Overview
Asuragen, Inc.
Company Overview
Beckman Coulter, Inc
Company Overview
Becton, Dickinson
Company Summary
Biocartis S.A.
Company Overview
Biodesix, Inc.
Company Overview
bioMerieux SA
BioReference Laboratories, Inc
Company Overview
biotheranostics, Inc.
Company Overview
CARDIODX, INC
Company Overview
CELERA ALAMEDA
Clarient, Inc
Company Overview
deCODE Genetics, Inc.
Company Overview
DiaGenic ASA
Company Overview
Genomic Health, Inc.
Company Overview
Genoptix Medical Laboratory
Company Overview
Illumina, Inc.
Company Overview
Johnson & Johnson
Company Overview
Life Technologies Corporation
Company Overview
Memory Dx
Company Overview
Myriad Genetics, Inc.
Company Overview
Nanostring Technologies, Inc.
Company Overview
OPKO Health, Inc.
Company Overview
Provista Dx
Company Overview
Qiagen N.V.
Company Overview
Roche
Company Overview
SIEMENS HEALTHCARE
Company Overview
Singulex, Inc
Company Overview
Tethys Bioscience
Company Overview
Thermo Fisher Scientific
Company Overview
APPENDIX: LIST OF CONTRIBUTORS
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1
The Global Medical Biomarker Market 2008-2018
Figure 1-1
The Global Medical Biomarker Market 2008-2018
Figure 1-2
The Global Medical Biomarker Market Estimated Market Share by Segment, 2013
CHAPTER TWO: INTRODUCTION TO THE MEDICAL BIOMARKERS INDUSTRY
Table 2-1
Differences Between DNA Biomarkers, DNA Tumor Biomarkers, and General Biomarkers
Table 2-2
Selected Biomarkers in Current Use
CHAPTER THREE: INDUSTRY TRENDS
Table 3-1
Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2011
Figure 3-1
Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2011
Table 3-2
Estimated World Population by Age and Geographical Region, 2012
Figure 3-2
Estimated World Population by Age and Geographical Region, 2012
Table 3-3
Average Life Expectancy in Years by Country 1980 and 2012
Figure 3-3
Average Life Expectancy in Years by Country 1980 and 2012
Table 3-4
Selected Disease Statistics, Worldwide, as at July 2012
Table 3-4
Elderly Support Ratio in Selected Countries (2050) (Note: Ratio is Number of 15 to 64 year olds for every 65+ year old.)
Table 3-5
Available Market Data, 2010
Table 3-6
BRIC Healthcare Infrastructure Capacity
CHAPTER FOUR: BIOMARKERS IN CANCER
Table 4-1
Viruses Associated with Cancer in Humans
Table 4-2
World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexes
Figure 4-1
Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 4-3
Total Cancer Incidence by Sex and Country, 2010 Estimates
Figure 4-2
Total Cancer Incidence by Sex and Country, 2010 Estimates
Table 4-4
Selected Cancer Biomarkers in Development
Table 4-5
Global Cancer Biomarker Market 2008-2018
Figure 4-3
Global Cancer Biomarker Market 2008-2018
Figure 4-4
Global Cancer Biomarker Market by Application, Clinical versus Research 2008-2018
Figure 4-5
The Global Cancer Clinical Biomarker Market by Select Cancer Type, (Breast, Lung, Leukemia, Others) 2013
Figure 4-6
Global Cancer Biomarker Market Estimated Market Share by region (US, EMEA, Other), 2013
Figure 4-7
Global Cancer Biomarker Market Leading Suppliers, Estimates for 2013
CHAPTER FIVE: BIOMARKERS IN CARDIOVASCULAR DISEASE AND BLOOD DISORDERS
Table 5-1
Selected Cardiac Markers in Development
Table 5-2
Global Cardiovascular and Blood Disorder Biomarker Market 2008-2018
Figure 5-1
Global Cardiovascular and Blood Disorder Biomarker Market 2008-2018
Figure 5-2
Global Cardiovascular and Blood Disorder Biomarker Market by Application, Clinical versus Research 2008-2018
Figure 5-3
The Global Cardiovascular and Blood Disorder Clinical Biomarker Market by Select Disorder/Disease, 2013 (Cardiac, Blood, Other)
Figure 5-4
Global Cardiovascular and Blood Disorder Biomarker Market Estimated Market Share by region (US, EMEA, Other), 2013
Figure 5-5
Global Cardiovascular Disease and Blood Disorder Biomarker Market, Leading Suppliers Estimates for 2013
CHAPTER SIX: BIOMARKERS IN ENDOCRINE AND IMMUNE DISORDERS
Table 6-1
Selected Endocrine, Autoimmune, Inflammatory and Other Markers in Development
Table 6-2
Global Endocrine and Immune Disorder Biomarker Market 2008-2018
Figure 6-1
Global Endocrine and Immune Disorder Biomarker Market 2008-2018
Figure 6-2
Global Endocrine and Immune Disorder Biomarker Market by Application, Clinical versus Research 2008-2018
Figure 6-3
The Global Endocrine and Immune Disorder Clinical Biomarker Market by Select Disorder/Disease, 2013
Figure 6-4
Global Endocrine and Immune Disorder Biomarker Market Estimated Market Share by region (US, EMEA, Other), 2013
CHAPTER SEVEN :BIOMARKERS IN INFECTIOUS DISEASE
Table 7-1
Selected Infectious Disease Markers in Development
Table 7-2
Global Infectious Disease Biomarker Market 2008-2018
Figure 7-1
Global Infectious Disease Biomarker Market 2008-2018
Figure 7-2
Global Infectious Disease Biomarker Market by Application, Clinical versus Research 2008-2018161
Figure 7-3
The Global Infectious Disease Clinical Biomarker Market by Select Disorder/Disease, 2013
Figure 7-4
Global Infectious Disease Biomarker Market Estimated Market Share by region (US, EMEA, Other), 2013
Figure 7-5
Global Infectious Disease Biomarker Market, Leading Suppliers Estimates for 2013
CHAPTER EIGHT: BIOMARKERS IN NERVOUS SYSTEM DISORDERS
Table 8-1
Selected Neurological Disease Markers in Development
Table 8-2
Global Nervous System Disorder Biomarker Market 2008-2018 (Infection, Nervous System, Cancer, Cardiovascular/Blood, Endocrine/Immune)
Figure 8-1
Global Nervous System Disorder Biomarker Market 2008-2018
Figure 8-2
Global Nervous System Disorder Biomarker Market by Application, Clinical versus Research 2008- 2018
Figure 8-3
Global Nervous System Disorder Biomarker Market Estimated Market Share by region (US, EMEA, Other), 2013
CHAPTER NINE: MARKET SUMMARY
Table 9-1
The Global Medical Biomarker Market 2008-2018
Figure 9-1
The Global Medical Biomarker Market 2008-2018
Figure 9-2
The Global Medical Biomarker Market Estimated Market Share by Segment, 2013
Figure 9-3
The Global Medical Biomarker Market Estimated Market Share by Application, 2013
Figure 9-4
Global Medical Biomarker Market by Application, Clinical versus Research 2008-2018
Figure 9-5
The Global Medical Biomarker Market Estimated Market Share by Geographic Region, 2013
COMPANY PROFILES
LIST OF CONTRIBUTORS
